Stock Movers: BRK, TSM, VRSK (Podcast)

Berkshire Hathaway shares rose after Q2 results, with operating earnings up 16% to nearly $13B and ~$4.5B in share buybacks alongside nearly $20B of equity purchases. TSMC moved higher after monthly sales jumped 45%, signaling steady AI hardware demand despite volatility. Verisk shares fell after a Delaware Chancery Court ruling ordering it to complete a $2.35B merger with AccuLynx, rejecting attempts to adjust the deal over antitrust-clearance concerns and awarding AccuLynx damages plus interest.

Analysis

BRK.B looks less like a one-day earnings pop and more like evidence that the cash overhang is finally being reduced into a market that still assigns a low-growth multiple to a very large capital allocator. The second-order effect is on valuation dispersion: if management is willing to buy back aggressively, the floor under book value and per-share compounding improves, but the upside is capped unless insurance underwriting stays benign and equity markets do the heavy lifting. This is a months-to-years story, not a tradeable catalyst unless buyback pace stays elevated.

TSM is the cleaner momentum signal because monthly sales strength matters most when the market is debating whether AI capex is a one-quarter pull-forward. If this persists, the beneficiaries are not just TSM but the entire high-end semiconductor stack: AMAT, LRCX, KLAC, and advanced packaging capacity providers should see tighter utilization and less pricing pressure. The contrarian risk is that monthly sales can overstate end-demand during inventory rebuilds; the thesis breaks if hyperscaler capex guides down or if the next two months of orders decelerate sharply.

VRSK is the negative asymmetry. A court forcing consummation raises the cost of walking away from strategic deals across data/software and likely widens the litigation discount for acquirers with antitrust exposure. That can depress M&A optionality premiums in the sector for 1-3 months, but the direct stock impact may be mostly trapped in the deal spread; the larger trade is a broader risk-off on buyers that depend on synergy-driven acquisitions. The reversal trigger is either a settlement, appellate stay, or a market conclusion that precedent is idiosyncratic rather than sector-wide.

Key Decisions for Investors

• Long TSM / short SMH on any 1-2 day pullback if volume confirms, targeting a 6-12 week continuation move as AI supply-chain names rerate on sustained shipment data; invalidation is two consecutive weaker monthly sales prints.
• Overweight AMAT, LRCX, and KLAC versus the SOX if TSM strength is matched by better ASML/CapEx commentary; this is a cleaner second-order expression than owning TSM outright, with 3-6 month upside if tool orders inflect.
• Treat BRK.B as a hold-to-modestly-positive compounding name rather than a chase; add only on market weakness if buyback intensity stays above the prior quarter, with the thesis broken by a slowdown in repurchases or underwriting deterioration.
• Use the VRSK ruling as a watchlist trigger for shorting deal-dependent software names on strength, not as an automatic short in VRSK itself; the better risk/reward is a basket short of high-M&A-optional software vs. quality compounders like SPGI over the next 1-3 months.